1 Aug 2014 09:22
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Issue of equity and Directors' shareholdings
1 August 2014, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that two Non-Executive Directors of the Company have taken part of their fees for the half-year ended 31 July 2014 in ordinary shares, resulting in the issue of 14,185 new ordinary shares (the "New Shares").
The New Shares were issued on 31 July 2014 at a price of 29.75 pence per share, being the average mid-market closing price for the five business days ending on the day of allotment. The allotment, total holding and the percentage of the current issued share capital ("ISC") following this allotment for each director are as follows:
Director | Shares allotted
| Ordinary sharesheld followingallotment | % ofISC | Optionsover ordinary shares ) | Options as% of ISC |
Oliver James | 9,075 | 145,310 | 0.06% | 118,020 | 0.05% |
Rajesh Chopra | 5,110 | 30,909 | 0.01% | - | - |
Application has been made to admit the New Shares to trading on AIM and dealings are expected to commence on 7 August 2014.
Following admission, the number of ordinary shares in issue in the Company will be 264,177,183. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.
Contacts:
e-Therapeutics plc
Steve Medlicott
Tel: +44 (0) 1993 883 125
www.etherapeutics.co.uk
N+1 Singer
Aubrey Powell / Jen Boorer
Tel: +44 (0)20 7496 3000
www.n1singer.com